EMD Serono

229 articles with EMD Serono

• Datamonitor Report: Merck Serono's Future MS Market Foothold Loosens

  2/18/2011

• Merck Serono: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX

  1/19/2011

• Domain Therapeutics and Merck Serono Announce $178M Agreement to Develop Drugs for Parkinson's Disease

  1/19/2011

• Recordati S.p.A Signs Co-Marketing Agreement With Merck Serono in France for Pitavastatin

  12/27/2010

• Merck Serono Adopts Agilent Technologies Inc.' Electronic Lab Notebook for Biology Research

  11/22/2010

• Flamel Technologies Announces Third Quarter Results; Achievement of Second Milestone in Fourth Quarter with Merck Serono

  11/5/2010

• Newron Pharmaceuticals, Merck Serono Drug, Safinamide Misses Goal In Parkinson's Phase III Study

  11/4/2010

• Flamel Technologies Achieves Clinical Milestone with Merck Serono on an Extended Release Formulation of Interferon beta-1a

  10/19/2010

• Merck Serono To Ask EU Agency To Reconsider MS Pill Cladribine

  10/11/2010

• Merck Serono Release: Results of a Randomized Phase II Study with Erbitux in Breast Cancer Highlighted in ESMO 2010 Presidential Symposium

  10/11/2010

• Merck Serono Release: Highlight Advancing Confidence in Erbitux as Only Targeted Treatment to Increase Survival and Potential for Cure in Head and Neck Cancer

  10/11/2010

• Merck Serono Release: Early Tumor Shrinkage with 1st Line Erbitux Therapy Leads to Longest-Ever Median Survival in KRAS Wild-Type mCRC

  10/11/2010

• Ablynx and Merck Serono Enter Into Second Agreement to Co-Discover and Co- Develop Nanobodies(R)

  10/11/2010

• Merck Serono Release: New Data for Erbitux in Prevalent Cancers to Be Revealed at ESMO

  10/4/2010

• Merck Serono to Create New Pharmaceutical Jobs in the United Arab Emirates (UAE)

  10/1/2010

• PregLem SA Announces In-Licensing Deal With Merck Serono For Post-Operative Adhesions & Endometriosis

  8/11/2010

• Merck Serono: Survey Shows the Number of mCRC Patients Tested for KRAS Jumped 50% in 12 Months

  7/1/2010

• Merck Serono Release: Cilengitide Study Provides Long-Term Follow-up Data in Glioblastoma Patients Receiving Investigational Drug for More Than 4 Years

  6/7/2010

• Clinical Data Announces FDA Acceptance of New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder; Triggers $15.6 Million Payment from Merck Serono

  5/24/2010

• Merck Serono Presents Further Evidence of Sustained Innovation in Oncology at ASCO 2010

  5/21/2010